Keywords: MDRNA, Cequent, RNAi platform, M&A

MDRNA expands oncology and RNAi platform with $46 million stock buy of Cequent Pharmaceuticals

Article | 06 April 2010

Print This

Two US RNAi-based drug discoverers and developers, MDRNA and Cequent Pharmaceuticals, have reached agreement to merge, with the latter being ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in